Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Oliver Sartor MD

Oliver Sartor MD

Director of the Radiopharmaceutical Trials, Chief of the Genitourinary Cancer Malignancy Group, Mayo Clinic, Rochester, Minnesota

Dr. Oliver Sartor is a medical oncologist in the Division of Medical Oncology in the Department of Oncology at the Mayo Clinic in Rochester, Minnesota. He serves as Chair of the Genitourinary Cancer Disease Group and the Director of Radiopharmaceutical Clinical Trials for the Mayo Clinic Comprehensive Cancer Center.

Dr. Sartor is an internationally recognized expert in prostate cancer. His medical practice and research have focused on prostate cancer since 1990 when he finished a medical oncology fellowship at the National Cancer Institute (NCI). He has published over 500 peer-reviewed articles, led or co-led multiple national and international clinical studies, including four phase III studies pivotal for FDA approval of drugs for advanced prostate cancer (Quadramet, Xofigo, Pluvicto, and Jevtana). He has lectured widely, and, at last count, has given invited lectures in 33 countries. He is the Medical Oncology Chair of the Genitourinary Cancer Committee of NRG, a national cancer research group.

Disclosures

  • Consultant: Advanced Accelerator Applications (AAA); Astellas; AstraZeneca; Bayer; Blue Earth Diagnostics; Bavarian Nordic; Bristol Myers Squibb; Clarity Pharmaceuticals; Clovis; Constellation; Dendreon; EMD Serono; Fusion; Isotopen Technologien Muenchen; Janssen; Merck; Myovant; Myriad; Noria Therapeutics; Novartis; Noxopharm; Progenics; POINT Biopharma; Pfizer; Sanofi; Teneobio; Telix; Theragnostics
  • Research funding: Advanced Accelerator Applications; Amgen; AstraZeneca; Bayer; Constellation; Endocyte; Invitae; Janssen; Lantheus; Merck; Progenics; Teneobio

Recent Contributions to PracticeUpdate:

  1. Association of Smoking Status With Recurrence, Metastasis, and Mortality Among Patients With Localized Prostate Cancer Undergoing Prostatectomy or Radiotherapy
  2. Implications on PSMA Targeted Therapy
  3. CTCs and Survival in Abiraterone- and Enzalutamide-Treated Patients With CRPC
  4. Few Patients Selected for Radical Prostatectomy Reach the Competing Mortality Rate of PIVOT
  5. Contextualizing PROSPER Data: Recommendations From ASCO GU 2018
  6. Radium-223 in mCRPC: Updates From ASCO GU 2018
  7. Patient-Reported Outcomes Following Abiraterone Acetate Plus Prednisone Added to ADT for Newly Diagnosed Metastatic Castration-Naïve Prostate Cancer
  8. 2017 Top Stories in Advanced Prostate Cancer: LATITUDE and STAMPEDE
  9. ADT No Longer the Standard of Care for Metastatic Prostate Cancer: An Expert Roundtable
  10. Integrating Genetic Testing for Prostate Cancer in Clinical Practice

Most Read This Week

Recently Updated